Ocugen, Inc (OCGN)

NASDAQ
1.840
-0.030(-1.60%)
After Hours
1.840
0.000(0.00%)
- Real-time Data
  • Volume:
    4,354,818
  • Day's Range:
    1.765 - 1.870
  • 52 wk Range:
    1.670 - 17.650

OCGN Overview

Prev. Close
1.87
Day's Range
1.765-1.87
Revenue
-
Open
1.81
52 wk Range
1.67-17.65
EPS
-0.307
Volume
4,354,818
Market Cap
398.48M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
5,262,586
P/E Ratio
-8.22
Beta
4.21
1-Year Change
-72.3%
Shares Outstanding
216,565,916
Next Earnings Date
Nov 11, 2022
What is your sentiment on Ocugen?
or
Market is currently closed. Voting is open during market hours.

Ocugen, Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Ocugen, Inc Analysis

Ocugen, Inc Company Profile

Ocugen, Inc Company Profile

Employees
15

Ocugen, Inc. is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing vaccine for COVID-19. The Company's technology pipeline includes: COVID-19 Vaccine (0.5), Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. COVID-19 Vaccine candidate is focused on developing, manufacturing and commercializing COVAXIN for the prevention of COVID-19 in humans in the Ocugen Covaxin Territory. COVAXIN is a whole-virion inactivated COVID-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus. The Modifier Gene Therapy platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). It is developing OCU200, a biologic product candidate to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet AMD. OCU400, its first product candidate being developed with its modifier gene therapy platform.

Read More

Analyst Price Target

Average5.833 (+217.01% Upside)
High8
Low3.5
Price1.84
No. of Analysts6
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyStrong BuyBuySellStrong Sell
Technical IndicatorsStrong BuyStrong BuyBuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyBuyStrong SellStrong Sell
  • up up up
    0
    • There’s still hope for ocugen 😁
      2
      • MALVERN, Pa., May 23, 2022 -- Ocugen, Inc., a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vaccines, today announced that the U.S. Food and Drug Administration (FDA) lifted the clinical hold on the Company’s Phase 2/3 clinical trial, OCU-002, for COVAXIN™ (BBV152). 'We’re extremely pleased..'
        1
        • April 25, 2022 7:33 AM EDT ~ Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial
          0
          • April 18, 2022 7:11 AM EDT ~ Ocugen, Inc. to Commercialize COVAXIN™ in Mexico, Rights Now Encompassing All of North America
            1
            • Pacob, covid is almost over in USA and Ocugen can only make money selling covaxin in USA. Furthermore, OCGN still has not submited an application to FDA, I believe. I am surprised stock price is still this high.
              1
            • new variant landed in Europe, time to take a deep breath, to savor this brief moment of freedom, soon you will miss it deeply
              2
            • lol You must live in a cave and believe all this. Do you live in USA?
              0
          • April 1, 2022 7:37 AM EDT ~ Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration
            0
            • Finally some green
              1
              • Back above my average 😎
                0
            • Tesla...😎😎😎😂
              5
              • Ocugen, $OCGN, request for pediatric use of COVID-19 vaccine rejected by FDA.
                2
              • more like Yugo.
                1
            • 1.5$
              4
              • no revenue🤣🤣🤣
                1
                • You are literally all over the place with this stock. Are u bullish or bearish? Make up your mind ffs
                  0
                • Ahahahahahaha
                  0
                • What a recognition. Has it ever been at all?
                  0